Welcome to our dedicated page for Aptorum Group news (Ticker: APM), a resource for investors and traders seeking the latest updates and insights on Aptorum Group stock.
Aptorum Group Ltd (APM) is a clinical-stage biopharmaceutical company pioneering novel therapies for oncology, infectious diseases, and unmet medical needs through innovative drug discovery platforms. This dedicated news hub provides investors and industry observers with comprehensive updates on the company's clinical developments, strategic partnerships, and regulatory progress.
Access timely announcements including clinical trial results, regulatory filings, and research collaborations, all centralized for efficient tracking of APM's advancements in therapeutic repurposing and microbiome-based therapies. Our curated collection features press releases covering key milestones in drug development, infectious disease solutions, and operational updates from both therapeutic and non-therapeutic business segments.
Stay informed about APM's progress in addressing orphan indications and women's health innovations through systematic updates. Bookmark this page for verified information on pipeline developments, presented with clarity for both professional investors and those new to biopharma tracking. Regular updates ensure you maintain current awareness of the company's position in competitive therapeutic markets.
Aptorum Group Limited (Nasdaq: APM) announced a special extraordinary meeting of shareholders on February 21, 2023, at its London office. The meeting will address proposals for a merger with a newly established subsidiary and a reduction in share par value from USD10 to USD0.00001. These changes aim to streamline company structure and improve capital efficiency. Details are available in a Form 6-K filed with the SEC on February 6, 2023. Aptorum is focused on the development of therapeutics for unmet medical needs, particularly in oncology, autoimmune diseases, and infectious diseases.
Aptorum Group Limited (NASDAQ: APM) announced a 1-for-10 reverse stock split effective January 23, 2023, approved by shareholders on December 21, 2022. The Company aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share by ensuring that its Class A Ordinary Shares maintain this price for at least 10 consecutive business days before May 16, 2023. The reverse split consolidates every 10 shares into 1, affecting both Class A and Class B shares. The new CUSIP number for Class A shares post-split is G6096M 114.
Aptorum Group Limited (Nasdaq: APM) has published a paper detailing a rapid low-depth unbiased metagenomics sequencing workflow for diagnosing infectious diseases using the PathsDx Test. This test achieved over 95% sensitivity and specificity, with 93% agreement with standard diagnostic tests. The paper emphasizes the versatility of Illumina platforms in detecting DNA and RNA pathogens. With a growing genomic database of nearly 20,000 species, Aptorum is expanding validation sites in Singapore, Hong Kong, and the U.S. to enhance its testing capabilities.
Aptorum Group Limited (Nasdaq: APM) held its 2022 annual general meeting on December 21, 2022, in London. Shareholders re-elected seven directors and confirmed the re-appointment of Marcum Asia CPAs LLP as independent auditors. A significant decision made was the approval of a share consolidation, where every 10 Class A Ordinary Shares will convert to 1 Class A Share, and the same ratio applies for Class B Ordinary Shares, effective before December 21, 2023. Following this consolidation, the authorized share capital will be $100,000,000 divided into 6 million Class A shares and 4 million Class B shares.
Aptorum Group Limited (NASDAQ: APM) has completed a private offering of USD $3 million in convertible notes due December 2023. The offering, subscribed by Aenco Technologies Limited, is aimed at supporting daily operations and clinical programs. The notes, which carry a 7% annual interest rate and a conversion price of $1.20 per share, are to be utilized primarily for R&D of therapeutic candidates and commercialization of its health products. This financing reflects strong insider support for Aptorum's strategic initiatives.
Aptorum Group Limited (Nasdaq: APM) announced a private offering of
Aptorum Group Limited (NASDAQ: APM) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on November 26, 2022, at 7 p.m. ET. CEO Darren Lui will discuss Aptorum's pipeline targeting oncology, autoimmune, and infectious diseases, highlighting a $15 billion market opportunity and the completion of Phase 1 trials. The interview can be accessed at this link.
Aptorum Group Limited (NASDAQ: APM) announces the publication of a validated analytical method for measuring plasma pro-EGCG and its metabolites. Developed in collaboration with The Chinese University of Hong Kong, the method uses ultra-performance liquid chromatography and is crucial for in vivo pharmacokinetic studies. The company aims to utilize this assay for future Phase 1 clinical trials of Pro-EGCG, targeting endometriosis, which affects approximately 10% of women of reproductive age according to WHO.
Aptorum Group Limited (NASDAQ: APM) received a deficiency letter from Nasdaq due to its Class A Ordinary Shares trading below the $1.00 minimum bid price for 30 straight business days. The company has until
Aptorum Group Limited (NASDAQ: APM) will hold its 2022 annual general meeting on December 21, 2022, at its London office. Shareholders as of October 14, 2022, can vote and receive notice for the meeting. The company filed its annual report on Form 20-F, including audited financials for the fiscal year ending December 31, 2021, with the SEC on April 29, 2022. Aptorum focuses on developing therapeutics for oncology and infectious diseases, having completed two Phase I clinical trials. For more details, visit their website.
